IM19 study for relapsed or refractory non-Hodgkin lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether IM19 can safely and effectively treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It is for adults with certain lymphoma markers and good overall functioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your lymphoma has come back (relapsed) or did not respond (refractory), confirmed by your tumor test showing CD19 positivity
- Your lymphoma also matches the specific types used in the study, and your CD20 status (if positive) is handled by the matching treatment plan
- You can be assessed for the disease using standard imaging/measurement rules (Lugano 2014)
- You’re well enough to do daily activities (ECOG 0 or 1) and expected to live more than 3 months
- You can and will sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new type of immune cell therapy, called IM19 CAR-T, can help people with lupus that hasn't gotten better with standard treatments. It is designed for people ages 18 to 65 with moderate to severe disease activity.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
This trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell non-Hodgkin’s lymphoma has come back or did not respond to standard treatments. It may help your immune system attack the cancer cells that carry a specific marker called CD19.
Hear when a new NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.